Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-[3-carboxymethyl-3-(4-phosphonooxy-benzyl)-ureido]-4-[(3-cyclohexyl-propyl)-methyl-carbamoyl]butyric acid
- Development stage
- Unknown
- Modality
- Modified Peptides → Peptides, Small Molecules
01
Overview
This compound is a synthetic, nonpeptide small molecule designed as a ligand for the Src homology 2 (SH2) domain of the Src family tyrosine kinases. It mimics phosphotyrosine-containing sequences and binds to the SH2 domain, thereby inhibiting protein-protein interactions mediated by this domain. The SH2 domain is critical in intracellular signaling pathways, particularly those involving tyrosine kinases such as Src, which are implicated in cancer and other diseases. This molecule was developed for proof-of-concept studies to explore inhibition of SH2-phosphoprotein interactions as a therapeutic strategy[5][6][8].
- Other names
- (4S)-4-{[(carboxymethyl)({[4-(phosphonooxy)phenyl]methyl})carbamoyl]amino}-4-[(3-cyclohexylpropyl)(methyl)carbamoyl]butanoic acid(4S)-4-(((carboxymethyl)(((4-(phosphonooxy)phenyl)methyl))carbamoyl)amino)-4-((3-cyclohexylpropyl)(methyl)carbamoyl)butanoic acid
Beyond the preview
Go deeper on 4-[3-carboxymethyl-3-(4-phosphonooxy-benzyl)-ureido]-4-[(3-cyclohexyl-propyl)-methyl-carbamoyl]butyric acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-[3-carboxymethyl-3-(4-phosphonooxy-benzyl)-ureido]-4-[(3-cyclohexyl-propyl)-methyl-carbamoyl]butyric acid.